Aleniglipron for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called aleniglipron to assess its effects on body composition in individuals with obesity. Participants will take either aleniglipron or a placebo (a pill with no active drug) for 40 weeks. The goal is to determine if aleniglipron reduces body fat more effectively than the placebo. Suitable candidates for this trial are those with a BMI of 30 or higher, who have not experienced significant weight changes recently, and do not have diabetes. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that aleniglipron is likely to be safe for humans?
Research shows that aleniglipron is being tested as a treatment for obesity. Although detailed safety information for aleniglipron is not yet available, its progression to a Phase 2 trial indicates it has passed initial safety checks. Phase 2 trials primarily assess how well participants tolerate the treatment and identify potential side effects.
Similar studies with drugs like aleniglipron, known as GLP-1 receptor agonists, have shown that treatments are usually well-tolerated. However, some individuals might experience mild to moderate side effects, such as nausea or diarrhea, which are common with these medications. The ongoing research aims to gather more detailed information on aleniglipron's safety and effectiveness, with participants closely monitored throughout the study.12345Why do researchers think this study treatment might be promising?
Researchers are excited about aleniglipron for obesity because it represents a potential new approach in a field dominated by lifestyle changes, medications like orlistat, and GLP-1 receptor agonists such as semaglutide. Aleniglipron is unique because it may work by targeting different pathways in the body to help regulate weight, potentially offering an alternative mechanism of action compared to existing treatments. Additionally, its oral administration could provide a more convenient option for patients compared to injectable therapies, making it a promising candidate in the fight against obesity.
What evidence suggests that aleniglipron might be an effective treatment for obesity?
Research has shown that aleniglipron, a treatment under study for obesity, yields promising results. In an earlier study, 67% of participants taking aleniglipron lost at least 6% of their weight, and 33% lost at least 10% by week 12. In contrast, none of the participants taking a placebo achieved these weight loss goals. In this trial, participants will receive either aleniglipron or a placebo to further evaluate its effectiveness. Aleniglipron helps control appetite and weight. These early findings suggest it could be a strong option for those seeking assistance with weight management.12346
Are You a Good Fit for This Trial?
This trial is for individuals with obesity, including childhood obesity. Participants will be chosen to receive either the study drug aleniglipron or a placebo without knowing which one they're getting. The ratio of participants receiving aleniglipron to placebo is 5:1.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 40 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Aleniglipron
Find a Clinic Near You
Who Is Running the Clinical Trial?
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Lead Sponsor